Recently, it has been shown that wild-type IDH1 is highly expressed in a variety of cancer types, including non-small cell lung carcinoma (NSCLC), primary glioblastomas (GBM), and several hematological malignancies and is correlated with disease progression [9]. Here, IDH1 is linked to non-small cell lung carcinoma.